The 10 most common questions about infective endocarditis
bacteremia; ceftriaxone; cost-effectiveness; diagnosis; echocardiography; Immunology; Infectious Diseases; staphylococcus-aureus-endocarditis; streptococci; suspected endocarditis; therapy
Watanakunakorn C
Infectious Diseases in Clinical Practice
2000
2000-09
Journal Article
<a href="http://doi.org/10.1097/00019048-200009070-00001" target="_blank" rel="noreferrer noopener">10.1097/00019048-200009070-00001</a>
Bimatoprost - a review
acid; aqueous-humor; bimatoprost; clinical-trial; cost-effectiveness; elevated intraocular-pressure; fixed combination; free; glaucoma; human eyes; Intraocular pressure; ocular hypertension; open-angle glaucoma; Pharmacology & Pharmacy; prostaglandin; prostaglandin-ethanolamides; prostamide; prostamides
Bimatoprost is a synthetic prostamide analog that is efficacious in the treatment of open-angle glaucoma, ocular hypertension and other forms of glaucoma. it reduces intraocular pressure (IOP) by increasing uveoscleral and trabecular outflow. When used as a 0.03% topical preparation once daily, it demonstrates sustained lowering of IOP of 7 - 8 mmHg over a 24-h period. The drug has been found to be more effective than timolol. In some studies it has shown greater ability to lower IOP when compared with other prostaglandin analogs; whereas in others all three clinically used prostaglandin analogs were found to be equally effective. it shows good IOP reduction when used in combination with other glaucoma medications. A common side effect includes mild conjunctival hyperemia, which is generally reversible. Other side effects include periorbital pigmentation, discomfort, ocular surface hyperemia and skin changes. Pharmacoeconomic data indicate that bimatoprost is cost effective in the treatment of open-angle glaucoma.
Patil A J; Vajaranant T S; Edward D P
Expert Opinion on Pharmacotherapy
2009
2009-11
Journal Article
<a href="http://doi.org/10.1517/14656560903292649" target="_blank" rel="noreferrer noopener">10.1517/14656560903292649</a>
Digital Breast Tomosynthesis: Cost-Effectiveness of Using Private and Medicare Insurance in Community-Based Health Care Facilities.
Female; Humans; Retrospective Studies; United States; breast cancer; Breast Neoplasms/*diagnostic imaging; *Cost-Benefit Analysis; Biopsy/methods; cost-effectiveness; digital breast tomosynthesis; Mammography/*economics; Medicare/*economics; screening mammography; Insurance; Health/*economics
OBJECTIVE: The purpose of this study was to determine whether digital breast tomosynthesis (DBT) is a cost-effective alternative to full-field digital mammography (FFDM) for both Medicare and privately insured patients undergoing screening mammography. MATERIALS AND METHODS: A retrospective data analysis was performed between July 15, 2013, and July 14, 2014, with data on women presenting for screening mammography that included any additional radiologic workup (n = 6319). Patients chose to undergo DBT or FFDM on the basis of personal preference, physician suggestion, and cost difference. The summation of findings over the
Hunter Sara A; Morris Colleen; Nelson Karl; Snyder Brandon J; Poulton Thomas B
AJR. American journal of roentgenology
2017
2017-05
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.2214/AJR.16.16987" target="_blank" rel="noreferrer noopener">10.2214/AJR.16.16987</a>